Nature Medicine, Published online: 05 March 2025; doi:10.1038/s41591-025-03566-1
Secondary and exploratory analyses of the phase 3 NRG GY018 trial show that, in patients with advanced or recurrent endometrial cancer, first-line treatment with pembrolizumab together with paclitaxel and carboplatin leads to prolonged progression-free survival, according to blinded independent central review.
